

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III ...
Q2 2026
Aug 6, 2026
Q1 2026
May 7, 2026
FY 2025
Feb 27, 2026
Q4 2025
Feb 27, 2026
Q3 2025
Nov 5, 2025